Genes, Cognition, and Their Interplay in Methamphetamine Use Disorder

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2025 Feb 26

PMID 40001609

Authors

Ramisha Khan

Alyna Turner

Michael Berk

Ken Walder

Susan Rossell

Alexandre A Guerin

Jee Hyun Kim

Affiliations

Soon will be listed here.

Abstract

Methamphetamine use disorder is a pressing global health issue, often accompanied by significant cognitive deficits that impair daily functioning and quality of life and complicate treatment. Emerging evidence highlights the potential role of genetic factors in methamphetamine use disorder, particularly in association with cognitive function. This review examines the key genetic and cognitive dimensions and their interplay in methamphetamine use disorder. There is converging evidence from several studies that genetic polymorphisms in , , , and are associated with protection against or susceptibility to the disorder. In addition, people with methamphetamine use disorder consistently displayed impairments in cognitive flexibility and inhibitory control compared with people without the disorder. These cognitive domains were associated with reactivity to methamphetamine cues that were positively correlated with total years of methamphetamine use history. Emerging research also suggests that inhibitory control is negatively correlated with lower blood mRNA levels, while cognitive flexibility positively correlates with higher blood mRNA levels, highlighting how genetic and cognitive dimensions interact in methamphetamine use disorder. We also include some future directions, emphasizing potential personalized therapeutic strategies that integrate genetic and cognitive insights. By drawing attention to the interplay between genes and cognition, we hope to advance our understanding of methamphetamine use disorder and inform the development of targeted interventions.

References

Schuldiner S, Shirvan A, Linial M . Vesicular neurotransmitter transporters: from bacteria to humans. Physiol Rev. 1995; 75(2):369-92. DOI: 10.1152/physrev.1995.75.2.369. View

Ghanooni D, Carrico A, Williams R, Glynn T, Moskowitz J, Pahwa S . Sexual Minority Stress and Cellular Aging in Methamphetamine-Using Sexual Minority Men With Treated HIV. Psychosom Med. 2022; 84(8):949-956. PMC: 9553259. DOI: 10.1097/PSY.0000000000001123. View

Dominguez-Salas S, Diaz-Batanero C, Lozano-Rojas O, Verdejo-Garcia A . Impact of general cognition and executive function deficits on addiction treatment outcomes: Systematic review and discussion of neurocognitive pathways. Neurosci Biobehav Rev. 2016; 71:772-801. DOI: 10.1016/j.neubiorev.2016.09.030. View

Connolly C, Foxe J, Nierenberg J, Shpaner M, Garavan H . The neurobiology of cognitive control in successful cocaine abstinence. Drug Alcohol Depend. 2011; 121(1-2):45-53. PMC: 3262906. DOI: 10.1016/j.drugalcdep.2011.08.007. View

Thomas D, Walker P, Benjamins J, Geddes T, Kuhn D . Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther. 2004; 311(1):1-7. DOI: 10.1124/jpet.104.070961. View

Bayne T, Brainard D, Byrne R, Chittka L, Clayton N, Heyes C . What is cognition?. Curr Biol. 2019; 29(13):R608-R615. DOI: 10.1016/j.cub.2019.05.044. View

Childress A, Hole A, Ehrman R, Robbins S, McLellan A, OBrien C . Cue reactivity and cue reactivity interventions in drug dependence. NIDA Res Monogr. 1993; 137:73-95. View

Lyoo I, Yoon S, Kim T, Lim S, Choi Y, Kim J . Predisposition to and effects of methamphetamine use on the adolescent brain. Mol Psychiatry. 2015; 20(12):1516-24. PMC: 5653271. DOI: 10.1038/mp.2014.191. View

Barr A, Panenka W, MacEwan G, Thornton A, Lang D, Honer W . The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci. 2006; 31(5):301-13. PMC: 1557685. View

10.

Truong J, Wilkins D, Baudys J, Crouch D, Johnson-Davis K, Gibb J . Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity. J Pharmacol Exp Ther. 2005; 314(3):1087-92. DOI: 10.1124/jpet.105.085951. View

11.

Mandell A, Morgan M . Amphetamine induced increase in tyrosine hydroxylase activity. Nature. 1970; 227(5253):75-6. DOI: 10.1038/227075a0. View

12.

Lecomte T, Dumais A, Dugre J, Potvin S . The prevalence of substance-induced psychotic disorder in methamphetamine misusers: A meta-analysis. Psychiatry Res. 2018; 268:189-192. DOI: 10.1016/j.psychres.2018.05.033. View

13.

Petry N, Alessi S, Olmstead T, Rash C, Zajac K . Contingency management treatment for substance use disorders: How far has it come, and where does it need to go?. Psychol Addict Behav. 2017; 31(8):897-906. PMC: 5714694. DOI: 10.1037/adb0000287. View

14.

Chiang K, Gerber A, Sipe J, Cravatt B . Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet. 2004; 13(18):2113-9. DOI: 10.1093/hmg/ddh216. View

15.

Jones B, Knapp L . Temporal temperature gradient electrophoresis for detection of single nucleotide polymorphisms. Methods Mol Biol. 2009; 578:153-65. DOI: 10.1007/978-1-60327-411-1_9. View

16.

Robbins T, Arnsten A . The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci. 2009; 32:267-87. PMC: 2863127. DOI: 10.1146/annurev.neuro.051508.135535. View

17.

Payer D, Nurmi E, Wilson S, McCracken J, London E . Effects of methamphetamine abuse and serotonin transporter gene variants on aggression and emotion-processing neurocircuitry. Transl Psychiatry. 2012; 2:e80. PMC: 3309557. DOI: 10.1038/tp.2011.73. View

18.

Ambrogini P, Torquato P, Bartolini D, Albertini M, Lattanzi D, Di Palma M . Excitotoxicity, neuroinflammation and oxidant stress as molecular bases of epileptogenesis and epilepsy-derived neurodegeneration: The role of vitamin E. Biochim Biophys Acta Mol Basis Dis. 2019; 1865(6):1098-1112. DOI: 10.1016/j.bbadis.2019.01.026. View

19.

Sanchez-Cubillo I, Perianez J, Adrover-Roig D, Rodriguez-Sanchez J, Rios-Lago M, Tirapu J . Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. J Int Neuropsychol Soc. 2009; 15(3):438-50. DOI: 10.1017/S1355617709090626. View

20.

Gonzalez R, Bechara A, Martin E . Executive functions among individuals with methamphetamine or alcohol as drugs of choice: preliminary observations. J Clin Exp Neuropsychol. 2007; 29(2):155-9. DOI: 10.1080/13803390600582446. View